Gene therapy company UniQure NV said on Friday the company’s experimental treatment for hemophilia B increased the levels of a protein that helps in blood clotting after 12 weeks in a relatively small study.
Prior infection with dengue, a mosquito-borne disease that infects nearly 400 million people a year, could reduce the risk of contracting Zika nearly by half, U.S. and Brazilian researchers reported.
Sanofi reportedly ended 38 R&D programs and is prioritizing oncology, immunology, rare disease and rare blood disorders.
New York City-based HiberCell launched with a $60.75 million Series A funding, led by ARCH Venture Partners.
GlaxoSmithKline is significantly reshaping to focus on pharmaceuticals, particularly a renewed interest in oncology treatments. As a result, the company made some cuts to the product pipeline, including six in GSK’s 2018 year-end report.
Just one in 20 U.S. children and teens gets the amount of sleep, exercise and screen time that doctors recommend for optimal health, a new study suggests.
Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis
Eli Lilly and Company and Incyte Corporation announced that baricitinib met the primary endpoint in BREEZE-AD1 and BREEZE-AD2, two Phase 3 studies evaluating the efficacy and safety of baricitinib monotherapy for the treatment of adult patients with moderate to severe atopic dermatitis.
Janssen Pharmaceutical, a Johnson & Johnson company, inked a worldwide collaboration and license deal with MeiraGTx to develop, manufacture and commercialize a portfolio of drugs for inherited retinal diseases.
Accelerated Evolution Biotechnologies’s claims to have found a cure for cancer are, appropriately, being met with global skepticism.